Esperion Therapeutics, Inc.
DelistedCIK 1434868fmd_1W9VGCXBMG1TSKR8C3GME2VNM8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Mar 31, 2026, 58 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 148 | 228 | 78 | 75 | 116 | 332 | 403 |
| Research and development | 58 | 148 | 171 | 176 | 147 | 106 | 119 | 86 | 46 | 48 |
| Selling, general and administrative | – | – | 33 | 66 | 200 | 185 | 109 | 143 | 163 | 166 |
| Total operating expenses | 76 | 169 | 205 | 241 | 349 | 305 | 255 | 272 | 278 | 343 |
| Operating income | (76) | (169) | (205) | (93) | (121) | (227) | (180) | (156) | 54 | 60 |
| Interest expense | 0 | 0 | 0 | 8 | 23 | 46 | 57 | 59 | 59 | 85 |
| Other non-operating income (expense) | 1 | 2 | 3 | 4 | 1 | 4 | 3 | 5 | 8 | 3 |
| Income before taxes | – | – | – | – | – | – | – | (209) | (52) | (21) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Net income from continuing operations | – | – | – | – | – | – | – | (209) | (52) | (23) |
| Net income | (75) | (167) | (202) | (97) | (144) | (269) | (234) | (209) | (52) | (23) |